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MEETING PROCEEDINGSLatest information for the thoracic surgeon from the Annual Meeting
of the American Society of Clinical Oncology
Sarita Dubey, MD,a and Giorgio Scagliotti, MD, PhDbThe 45th Annual Meeting of the American Society of Clin-
ical Oncology was held May 29 through June 2, 2009, in
Orlando, Florida. This review briefly summarizes new find-
ings about early non–small cell lung cancer (NSCLC) pre-
sented at this meeting.
SURGICAL QUALITY
Accurate lymph node (LN) staging is prognostic in early
surgical NSCLC. Sampling of at least 10 LNs is recommen-
ded at the time of surgery; however, practice patterns among
surgeons vary. A retrospective analysis of patient records
undergoing resection confirmed improved survival with
the National Comprehensive Cancer Network guideline–
based Good Quality Resection (negative margins, minimum
segmentectomy, LN sampling from stations 10–14, and>2
mediastinal stations).1 The 3–year survivals for those with
and without a Good Quality Resection were 72% and
63%, respectively (P ¼ .5). The paramount reason for
lack of Good Quality Resection was the lack of LN sam-
pling, with 2 mediastinal LN samples in 18% of the cases
and 3 or more in only 10%. Almost a third of the patients
did not have sampling of a mediastinal LN.1,2
DIAGNOSTIC PATHOLOGY
Although histologic type has not consistently been associ-
ated with clinical outcome in advanced NSCLC, it has re-
cently emerged as a potential predictive factor of response
or survival with respect to specific chemotherapeutic agents.
Histologic diagnoses rely on cellular architecture and immu-
nohistochemical analysis. To ascertain the diagnostic repro-
ducibility of a diagnosis of squamous cell carcinoma, 96
samples from a surgical cohort were prospectively examined
by lung cancer ‘‘expert’’ and ‘‘community’’ pathologists.3
Slides were scored according to 44 World Health Organiza-
tion diagnostic categories. Overall, the level of agreement
between pathologists with the hematoxylin–eosin staining
for diagnosis of squamous versus nonsquamous carcinoma
was only moderate (k coefficient 0.55, 95% confidence in-
terval [CI] 0.55–0.58). Agreement was proportional to the
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creased with better differentiated carcinoma (51% with
moderately differentiated carcinoma and 35% with poorly
differentiated).
PREDICTORS OF OUTCOME
In a prospective and observational study, patients sched-
uled to undergo pulmonary resection performed a preopera-
tive incremental exercise test with expired gas analysis to
assess cardiorespiratory fitness (peak oxygen consumption).
Cox proportional hazards models estimated the risk of all-
cause mortality according to cardiorespiratory fitness
category defined by peak oxygen consumption (<0.96 L
min1, 0.96–1.29 L min1, and>1.29 L min1), with adjust-
ment for age, sex, and performance status. Of the 398 pa-
tients, 335 underwent surgical resection and 63 were
deemed not eligible for resection. Median follow-up was
30.8 months, and 294 deaths were reported during this pe-
riod. For the entire sample, mortality rates declined across
increasing peak oxygen consumption categories (adjusted
Ptrend ¼ .012).4
Following up on the previously reported results about
ERCC1 and p27 in the International Adjuvant Lung Trial
(IALT-Bio), investigators presented new data about
MSH2, a DNA repair gene. The study demonstrated the
predictive values of ERCC1 and MSH2 statuses in resected
tumors.5 Similar to ERCC1 data, cisplatin-based adjuvant
chemotherapy improved survival in the MSH2-negative
group (hazard ratio [HR] for death 0.76, 95% CI 0.59–
0.97, P ¼ .03) but not the MSH2-positive group (HR for
death 1.12, 95% CI 0.81–1.55, P ¼ .48). In patients with
tumors negative for both markers, a survival improvement
with cisplatin chemotherapy was maintained (HR for death
0.65, 95% CI 0.47–0.91, P ¼ .01), whereas survival ap-
peared to be the worst for patients whose tumors expressed
both ERCC1 and MSH2 and who received cisplatin chemo-
therapy (HR for death 1.32, 95% CI 0.88–1.99, P ¼ .19).5
These biomarker analyses have demonstrated the effect of
patient selection on improving modest outcomes.
PERIOPERATIVE CHEMOTHERAPY
Few studies have shown benefits of neoadjuvant chemo-
therapy in select subsets of patients. Pooling results of the
published neoadjuvant studies, however, meta-analyses
have provided evidence of a statistically significant survival
benefit with chemotherapy of a magnitude similar to that
provided by adjuvant chemotherapy. The NeoAdjuvant
Taxol Carboplatin Hope (NATCH) trial was designed tordiovascular Surgery c Volume 138, Number 4 1039
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apy followed by surgery or surgery followed by adjuvant
chemotherapy.6 Six-hundred twenty-four patients with stage
I (>2 cm), II, and T3N1 were randomly allocated to the three
arms (Figure 1). The 5-year disease-free survival did not
show any significant difference among the three arms. The
5-year and median disease-free survivals were 39% and
28 months for surgery alone, 40.5% and 32 months for pre-
operative chemotherapy (P ¼ .17 vs surgery alone), and
39.3% and 24 months for postoperative chemotherapy
(P ¼ .73 vs surgery). No differences in overall survival
were observed. Response to induction chemotherapy was
53%, including a 9% rate of complete response. Neoadju-
vant therapy was better tolerated than was adjuvant chemo-
therapy, with 90% of patients receiving all planned cycles of
treatment versus only 62% of patients in the adjuvant arm.
Although the study did not show differences in survival
among the three treatments, NATCH did emphasize the
greater tolerability of chemotherapy before surgery and the
absence of increased postoperative mortality.
Long-term follow up of the JBR.10 study confirmed the
survival benefit of adjuvant cisplatin with vinorelbine.7 In
this study, which enrolled patients with stage IB and II dis-
ease, after 9.3-year median follow-up this benefit continued
to be confined to those with N1 disease (HR for death 0.68,
95% CI 0.5–0.9) and T2N0 tumors of at least 4 cm (HR for
death 0.66, 95% CI 0.3–1.1). At long-term follow up, there
was a significant reduction in disease-related deaths with
adjuvant chemotherapy (P ¼ .02).
PROPHYLAXIS AFTER DEFINITIVE TREATMENT
Brain metastases constitute 30% of failures after defini-
tive treatment for stage III NSCLC. Unable to accrue suffi-
FIGURE 1. NeoAdjuvant Taxol Carboplatin Hope (NATCH) study
schema. chemo, Chemotherapy; Adj chemo, adjuvant chemotherapy; pre-
op, preoperative; AUC, area under the concentration curve.1040 The Journal of Thoracic and Cardiovascular Sucient patients to meet its goal, the RTOG 0214 study
closed prematurely after randomly allocating only 356 out
of 1058 planned patients to receive prophylactic cranial irra-
diation (PCI) or observation after locoregional treatment
with surgery or radiation for stage III disease.8 Even though
PCI significantly reduced the 1-year incidence of brain me-
tastases (18% vs 7.7%, P¼ .004), there were no differences
in 1-year overall survival (76% PCI, 77% observation, P ¼
.86). Plausible explanations include insufficient numbers to
find a true difference in survival with PCI and a lack of im-
pact of brain metastases on overall survival because NSCLC
is a systemic disease.
SUMMARY
Survival of patients with NSCLC has improved incremen-
tally during the last decade. Continued follow-up of adjuvant
clinical trials underscores the durable benefits of adjuvant
chemotherapy. The magnitudes of these improvements,
however, have been modest. Retrospective analyses suggest
that these benefits can be improved further by patient selec-
tion with molecular profiling of the tumors. Ongoing clinical
trials will validate these findings prospectively. Efforts need
to be made to generalize findings of research advances. For
example, there is a pressing need for standardization of
adequate LN dissection in surgical patients. To affect out-
comes further, advances in technology need to be accompa-
nied by validation, reproducibility, and, most importantly,
universal availability.
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